Clinical Trials Logo

Clinical Trial Summary

In six communities we will seek out households where someone who has a history of respiratory problems. For the first winter we will measure temperature and humidity of the house and health of occupants. We will insulate half the houses and the next winter compare them with the uninsulated houses to see if warmer houses improve health.


Clinical Trial Description

Damp, cold indoor environments are bad for the health of people who live in them, particularly if they have respiratory problems or are vulnerable, such as the young or the very old. This is a community based study designed to test the hypothesis that insulating domestic houses will make them warmer and that this increase in indoor temperature will improve their health and wellbeing.

Following two pilot studies, the first among older people in city council flats and the second among home owners in Waitara. We have followed the "Waitara model" where community networks will be mobilised to identify households in each community where there is someone with a on going respiratory problem. Seven communities have been selected to help test these hypotheses and have agreed to participate Otara, Gisborne, Mahia/Nuhaka, Taranaki, Porirua, West Coast and Christchurch. Low income areas with high Maori populations have been deliberately selected to maximise the potential health gains.

Two hundred houses in each community will be insulated free of charge to the occupants. The workers who will insulate the homes will be local people employed through the Department of Work and Income (WINZ).

Once the houesholds are selected they will be randomly assigned to intervention or control groups. During the first winter, all 1400 households will be monitored for temperature and humidity and their comfort, health and healthcare utilization will be recorded. Half the households, assigned to the intervention group, will be fully insulated during the spring. The following winter, all the initial measurements taken from both the intervention and control group will be repeated. At the end of the study period, all control houses will be insulated.

This study has developed from a natural intervention being carried out by the Energy Efficiency Conservation Authority (EECA) to insulate domestic houses in New Zealand and is a major collaborative effort, which will shed light on the effectiveness of insulation in improving health and wellbeing. The impact of housing refurbishment on health has not previously been examined. There is considerable government and policy interest in promoting healthy housing and there is strong community interest in ensuring the housing stock is improved in order to lower health risks. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT00437541
Study type Interventional
Source University of Otago
Contact
Status Completed
Phase N/A
Start date July 2001
Completion date December 2002

See also
  Status Clinical Trial Phase
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device